Literature DB >> 11959550

Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme.

Peter Borowski1, Melanie Lang, Annemarie Haag, Herbert Schmitz, Joonho Choe, Huan-Ming Chen, Ramachandra S Hosmane.   

Abstract

Compounds that interact with DNA or RNA generally act as inhibitors of enzymes that unwind DNA or RNA. In the present study we describe the synthesis and properties of some nucleoside analogues that interact with double-stranded DNA but that, in contrast, facilitate the unwinding reaction mediated by West Nile (WN) virus nucleoside triphosphatase (NTPase)/helicase. The nucleoside analogues described, 1-(2'-O-methyl-beta-D-ribofuranosyl)imidazo[4,5-d]pyridazine-4,7(5H,6H)-dione (HMC-HO4), 1-(beta-D-ribofuranosyl)imidazo[4,5-d]pyridazine-4,7(5H,6H)-dione, and 1-(2'-deoxy-alpha-D-ribofuranosyl)imidazo[4,5-d]pyridazine-4,7(5H,6H)dione, all contain the imidazo[4,5-d]pyridazine ring system. The extent of the enhancing effect on helicase activity was found to be dependent on the time of exposure of the DNA substrate to the compounds and their concentrations. The nucleoside analogues were nevertheless found to be capable of uncoupling the ATPase and helicase activities of the enzyme by a mechanism operating on the level of the enzyme. Thus, in the case of HMC-HO4, the direct interaction with the enzyme caused inhibition of its helicase activity, with a half-maximal inhibitory concentration of 30 microM. The similar potency of the compound against replication of WN virus in cell culture suggests that inhibition of the helicase activity of the viral enzyme is responsible for the observed antiviral activity of HMC-HO4 and may indeed represent an important mode of action of antiviral drugs in general. Comparative studies performed with the related NTPase/helicase from hepatitis C virus revealed that the extent of the effects mediated by imidazo[4,5-d]pyridazine nucleosides is enzyme specific. The substances described may represent a starting point for the development of a new class of helicase-specific antivirals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959550      PMCID: PMC127168          DOI: 10.1128/AAC.46.5.1231-1239.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Translocation step size and mechanism of the RecBC DNA helicase.

Authors:  P R Bianco; S C Kowalczykowski
Journal:  Nature       Date:  2000-05-18       Impact factor: 49.962

2.  Probing the relationship between RNA-stimulated ATPase and helicase activities of HCV NS3 using 2'-O-methyl RNA substrates.

Authors:  T Hesson; A Mannarino; M Cable
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control.

Authors:  C T Wittwer; K M Ririe; R V Andrew; D A David; R A Gundry; U J Balis
Journal:  Biotechniques       Date:  1997-01       Impact factor: 1.993

5.  The RNA helicase and nucleotide triphosphatase activities of the bovine viral diarrhea virus NS3 protein are essential for viral replication.

Authors:  B Gu; C Liu; J Lin-Goerke; D R Maley; L L Gutshall; C A Feltenberger; A M Del Vecchio
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Biochemical properties of a minimal functional domain with ATP-binding activity of the NTPase/helicase of hepatitis C virus.

Authors:  P Borowski; R Kuehl; O Mueller; L H Hwang; J Schulze Zur Wiesch; H Schmitz
Journal:  Eur J Biochem       Date:  1999-12

7.  ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy.

Authors:  P Borowski; O Mueller; A Niebuhr; M Kalitzky; L H Hwang; H Schmitz; M A Siwecka; T Kulikowsk
Journal:  Acta Biochim Pol       Date:  2000       Impact factor: 2.149

8.  The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3).

Authors:  C L Tai; W K Chi; D S Chen; L H Hwang
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

9.  Antihelicase action of CI-958, a new drug for prostate cancer.

Authors:  L Lun; P M Sun; C M Trubey; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1998       Impact factor: 3.333

10.  Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus.

Authors:  P Gallinari; D Brennan; C Nardi; M Brunetti; L Tomei; C Steinkühler; R De Francesco
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more
  19 in total

Review 1.  Understanding helicases as a means of virus control.

Authors:  D N Frick; A M I Lam
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 2.  Isothermal DNA amplification in vitro: the helicase-dependent amplification system.

Authors:  Yong-Joo Jeong; Kkothanahreum Park; Dong-Eun Kim
Journal:  Cell Mol Life Sci       Date:  2009-07-24       Impact factor: 9.261

Review 3.  Molecular targets for flavivirus drug discovery.

Authors:  Aruna Sampath; R Padmanabhan
Journal:  Antiviral Res       Date:  2008-09-15       Impact factor: 5.970

4.  High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery.

Authors:  Francesc Puig-Basagoiti; Tia S Deas; Ping Ren; Mark Tilgner; David M Ferguson; Pei-Yong Shi
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  An investigation of phenylthiazole antiflaviviral agents.

Authors:  Abdelrahman S Mayhoub; Mansoora Khaliq; Carolyn Botting; Ze Li; Richard J Kuhn; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2011-05-03       Impact factor: 3.641

6.  5'-Silylated 3'-1,2,3-triazolyl Thymidine Analogues as Inhibitors of West Nile Virus and Dengue Virus.

Authors:  Sanjeev Kumar V Vernekar; Li Qiu; Jing Zhang; Jayakanth Kankanala; Hongmin Li; Robert J Geraghty; Zhengqiang Wang
Journal:  J Med Chem       Date:  2015-05-04       Impact factor: 7.446

7.  Triaryl pyrazoline compound inhibits flavivirus RNA replication.

Authors:  Francesc Puig-Basagoiti; Mark Tilgner; Brett M Forshey; Sean M Philpott; Noel G Espina; David E Wentworth; Scott J Goebel; Paul S Masters; Barry Falgout; Ping Ren; David M Ferguson; Pei-Yong Shi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

8.  Identification of novel small-molecule inhibitors of West Nile virus infection.

Authors:  Amine O Noueiry; Paul D Olivo; Urszula Slomczynska; Yi Zhou; Ben Buscher; Brian Geiss; Michael Engle; Robert M Roth; Kyung Min Chung; Melanie Samuel; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: synthesis and in vitro screening of 4-carbamoyl-5-(4,6-diamino-2,5-dihydro-1,3,5-triazin-2-yl)imidazole-1-beta-D-ribofuranoside.

Authors:  Ravi K Ujjinamatada; Andrea Baier; Peter Borowski; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2007-01-27       Impact factor: 2.823

10.  Sultam thiourea inhibition of West Nile virus.

Authors:  Eric Barklis; Amelia Still; Mohammad I Sabri; Alec J Hirsch; Janko Nikolich-Zugich; James Brien; Tenzin Choesang Dhenub; Isabel Scholz; Ayna Alfadhli
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.